Fig. 8From: Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A/B and β-amyloid inhibitors for Alzheimer’s diseaseStandards scopoletin (C4) and galantamine (C5)Back to article page